Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
July 01 2020 - 4:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it
will host a Virtual Investor and Analyst Day on Wednesday, July 15,
2020 from 8:30 AM to 11:30 AM ET. Members of Cytokinetics’ senior
management will be joined by expert clinicians and patients to
provide updates on the company’s advancing cardiovascular pipeline
and strategies to build a commercial franchise.
Panel discussions on the changing landscape in
heart failure therapy and emerging treatments for hypertrophic
cardiomyopathy (HCM) will feature the following physician
experts:
- John McMurray, M.D., Professor of Medical
Cardiology & Honorary Consultant Cardiologist, Institute of
Cardiovascular & Medical Sciences, BHF Cardiovascular Research
Centre, University of Glasgow
- Adrian Hernandez, M.D., MHS, Executive
Director, Duke Clinical Research Institute, Vice Dean, Duke
University School of Medicine
- Larry Allen, M.D., MHS, Professor of Medicine,
Kenneth Poirier Chair; Associate Head for Clinical Affairs,
Cardiology; Medical Director, Advanced Heart Failure, University of
Colorado School of Medicine
- Martin Maron, M.D., Director Hypertrophic
Cardiomyopathy Center, Tufts Medical Center and Chanin T. Mast
Hypertrophic Cardiomyopathy Center, Morristown Medical Center
- Anjali Tiku Owens, M.D., Medical Director,
Center for Inherited Cardiac Disease, Assistant Professor of
Medicine, University of Pennsylvania
- Andrew Wang, M.D., Professor of Medicine, Vice
Chief for Clinical Services, Duke University School of
Medicine
In addition, a patient panel discussion will
explore perspectives in both heart failure and HCM.
Interested parties may access the live virtual
event by registering online at https://bit.ly/CYTKInvestorDay or by
visiting the Investors & Media section of Cytokinetics’ website
at www.cytokinetics.com. An archived replay of the virtual event
will be available via Cytokinetics’ website until July 15,
2021.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators and next-in-class
muscle inhibitors as potential treatments for debilitating diseases
in which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen
Inc. (Amgen) to develop omecamtiv mecarbil, a novel cardiac
muscle activator. Omecamtiv mecarbil is the subject of an
international clinical trials program in patients with heart
failure including GALACTIC-HF and METEORIC-HF. Amgen holds an
exclusive worldwide license to develop and
commercialize omecamtiv mecarbil with a sublicense held
by Servier for commercialization in Europe and
certain other countries. Cytokinetics is
developing reldesemtiv, a fast skeletal muscle troponin
activator (FSTA) for the potential treatment of ALS and other
neuromuscular indications following conduct of FORTITUDE-ALS and
other Phase 2 clinical trials. The company is considering potential
advancement of reldesemtiv to Phase 3 pending ongoing
regulatory interactions. Cytokinetics is collaborating
with Astellas Pharma Inc. (Astellas) to research, develop and
commercialize other novel mechanism skeletal sarcomere activators
(not including FSTAs). Licenses held by Amgen and Astellas are
subject to specified co-development and co-commercialization rights
of Cytokinetics. Cytokinetics is also developing
CK-274, a novel cardiac myosin inhibitor that company scientists
discovered independent of its collaborations, for the potential
treatment of hypertrophic cardiomyopathies
(HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2
clinical trial of CK-274 in patients with obstructive
HCM. Cytokinetics continues its over 20-year history of
pioneering innovation in muscle biology and related pharmacology
focused to diseases of muscle dysfunction and conditions of muscle
weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:CytokineticsDiane Weiser
Senior Vice President, Corporate
Communications, Investor Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024